Liraglutide attenuates high glucose-induced abnormal cell migration proliferation and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor and inhibiting ERK1/2 and PI3K/Akt signaling pathways

摘要

BackgroundAs a new anti-diabetic medicine, Liraglutide (LIRA), one of GLP-1 analogues, has been found to have an anti-atherosclerotic effect. Since vascular smooth muscle cells (VSMCs) play pivotal roles in the occurrence of diabetic atherosclerosis, it is important to investigate the role of LIRA in reducing the harmful effects of high-glucose (HG) treatment in cultured VSMCs, and identifying associated molecular mechanisms.